Literature DB >> 21571685

Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion.

Gemma Brufau1, Albert K Groen, Folkert Kuipers.   

Abstract

Reverse cholesterol transport (RCT) is usually defined as high-density lipoprotein-mediated transport of excess cholesterol from peripheral tissues, including cholesterol-laden macrophages in vessel walls, to the liver. From the liver, cholesterol can then be removed from the body via secretion into the bile for eventual disposal via the feces. According to this paradigm, high plasma high-density lipoprotein levels accelerate RCT and hence are atheroprotective. New insights in individual steps of the RCT pathway, in part derived from innovative mouse models, indicate that the classical concept of RCT may require modification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571685     DOI: 10.1161/ATVBAHA.108.181206

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

Review 1.  Regulation of lipid stores and metabolism by lipophagy.

Authors:  K Liu; M J Czaja
Journal:  Cell Death Differ       Date:  2012-05-18       Impact factor: 15.828

2.  Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice.

Authors:  Yang Xu; Fei Li; Munaf Zalzala; Jiesi Xu; Frank J Gonzalez; Luciano Adorini; Yoon-Kwang Lee; Liya Yin; Yanqiao Zhang
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

Review 3.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

Review 4.  High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Authors:  Salman Bandeali; John Farmer
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

Review 5.  Biliary and nonbiliary contributions to reverse cholesterol transport.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Curr Opin Lipidol       Date:  2012-04       Impact factor: 4.776

Review 6.  Intestinal nuclear receptors in HDL cholesterol metabolism.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  J Lipid Res       Date:  2014-07-28       Impact factor: 5.922

7.  Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice.

Authors:  Marleen Schonewille; Jan Freark de Boer; Laura Mele; Henk Wolters; Vincent W Bloks; Justina C Wolters; Jan A Kuivenhoven; Uwe J F Tietge; Gemma Brufau; Albert K Groen
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

8.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

9.  Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice.

Authors:  Ping Xie; Lin Jia; Yinyan Ma; Juanjuan Ou; Hongming Miao; Nanping Wang; Feng Guo; Amirfarbod Yazdanyar; Xian-Cheng Jiang; Liqing Yu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-07       Impact factor: 8.311

10.  A novel approach to oral apoA-I mimetic therapy.

Authors:  Arnab Chattopadhyay; Mohamad Navab; Greg Hough; Feng Gao; David Meriwether; Victor Grijalva; James R Springstead; Mayakonda N Palgnachari; Ryan Namiri-Kalantari; Feng Su; Brian J Van Lenten; Alan C Wagner; G M Anantharamaiah; Robin Farias-Eisner; Robin Farias-Eisener; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2013-02-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.